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Leptospirosis is a potentially fatal bacterial zoonosis that is endemic throughout the tropics
and may be misdiagnosed as dengue. Delayed hospital admission of leptospirosis patients
is associated with increased mortality.
Methodology/Principal Findings
During a concurrent dengue/leptospirosis epidemic in Puerto Rico in 2010, suspected dengue
patients that tested dengue-negative were tested for leptospirosis. Fatal and non-fatal hospi-
talized leptospirosis patients were matched 1:1–3 by age. Records from all medical visits
were evaluated for factors associated with fatal outcome. Among 175 leptospirosis patients
identified (4.7 per 100,000 residents), 26 (15%) were fatal. Most patients were older males
and had illness onset during the rainy season. Fatal case patients first sought medical care
earlier than non-fatal control patients (2.5 vs. 5 days post-illness onset [DPO], p < 0.01), but
less frequently first sought care at a hospital (52.4% vs. 92.2%, p < 0.01). Although fatal
cases were more often diagnosed with leptospirosis at first medical visit (43.9% vs. 9.6%, p =
0.01), they were admitted to the hospital no earlier than non-fatal controls (4.5 vs. 6 DPO, p =
0.31). Cases less often developed fever (p = 0.03), but more often developed jaundice,
edema, leg pain, hemoptysis, and had a seizure (p 0.03). Multivariable analysis of labora-
tory values from first medical visit associated with fatal outcome included increased white
blood cell (WBC) count with increased creatinine (p = 0.001), and decreased bicarbonate with
either increasedWBC count, increased creatinine, or decreased platelet count (p < 0.001).
Conclusions/Significance
Patients with fatal leptospirosis sought care earlier, but were not admitted for care any ear-
lier than non-fatal patients. Combinations of routine laboratory values predictive of fatal
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outcome should be considered in admission decision-making for patients with suspected
leptospirosis.
Author Summary
Leptospirosis is a common tropical illness that results from exposure to the urine of ani-
mals infected with Leptospira bacteria. Because leptospirosis shares signs and symptoms
with other common tropical illnesses such as dengue, identification of patients with lepto-
spirosis can be challenging. Early identification of patients with leptospirosis is necessary
to initiate antibiotic therapy and in some cases provide in-hospital management. During
an epidemic of leptospirosis in Puerto Rico that occurred during a concomitant dengue
epidemic, we identified leptospirosis patients by screening specimens from suspected den-
gue patients. Of 175 leptospirosis patients identified, 26 (15%) died. After comparing lep-
tospirosis patients that died to patients of a similar age that were hospitalized but survived,
we observed that fatal cases were more often sent home after their first medical visit. We
next identified several routinely available laboratory values from patients’ first medical
visit that were associated with patients that died. Clinicians can use such laboratory values
to diagnose and hospitalize leptospirosis patients at increased risk for fatal outcome.
Introduction
Leptospirosis is an emerging zoonosis caused by infection with bacterial spirochetes of the
genus Leptospira, and is endemic throughout the tropics where>1 million cases and ~60,000
deaths occur annually [1, 2]. Human infection typically occurs through direct or indirect con-
tact with the urine of infected animals [1]. Leptospirosis is typically a mild acute febrile illness
(AFI); however, ~10% of patients progress to severe leptospirosis with acute kidney failure,
jaundice, and/or pulmonary hemorrhage [1, 3]. The case-fatality rate for patients with severe
leptospirosis ranges from 5–20% [4–6].
Due to similar clinical presentations, leptospirosis may be misdiagnosed as dengue [7–9].
Delayed or misdiagnosis of leptospirosis patients has been associated with increased mortality,
potentially due to delayed administration of antibiotics [10–15]. Therefore, identification of
early clinical markers of patients at risk for severe disease to thereby enable earlier patient
admission may result in improved outcome. Severe thrombocytopenia, increased serum creati-
nine or BUN, hemoptysis, dyspnea, and jaundice have been associated with severe or fatal out-
come in leptospirosis patients [5, 12, 14–18]; however, few studies have captured data from
patients’ entire clinical course to identify demographic characteristics, clinical findings, or
missed opportunities in clinical management associated with poor outcome [12, 14]. Conse-
quently, early clinical indicators of patients that have or will develop severe disease have not
been well elucidated.
During 1990–2014, a total of 729 leptospirosis cases were reported to Puerto Rico Depart-
ment of Health (PRDH), of which 78 (10.7%) were fatal (S1 Fig). Such surveillance enabled
documentation of leptospirosis epidemics in 2006, 2007, and 2010. However, because of under-
reporting of leptospirosis [19], which is attributable in part to misdiagnosis as dengue [20–22],
it is unclear if these data represent the true epidemiologic trends of leptospirosis. Factors asso-
ciated with severe or fatal outcome in leptospirosis patients have not previously been investi-
gated in Puerto Rico.
Risk Factors for Fatal Leptospirosis
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To better understand the epidemiology of leptospirosis during the 2010 dengue epidemic in
Puerto Rico [23], we conducted enhanced surveillance by performing leptospirosis diagnostic
testing on specimens from suspected dengue patients. We also reviewed medical records from
all health care visits of identified leptospirosis patients to identify demographic characteristics,




This study was approved by the Institutional Review Board at the Centers for Disease Control
and Prevention (CDC) (protocol # 6285).
Data sources and diagnostic testing
Leptospirosis cases in Puerto Rico in 2010 were identified from four sources. First, suspected
dengue cases reported via the Passive Dengue Surveillance System (PDSS) [24] that had no evi-
dence of dengue virus (DENV) infection by rRT-PCR or anti-DENV IgM ELISA [23]
(N = 2,519) were eligible to be tested for evidence of Leptospira spp. infection by microscopic
agglutination test (MAT) [25] and polymerase chain reaction (PCR) with primers specific for
Leptospira spp. LipL32 [26]. Specimens selected for leptospirosis testing (n = 1,133) came from
cases for which either: a) paired acute and convalescent specimens were available (n = 654); or
b) only a convalescent specimen was available and the case had reported fever, body pain or
headache, and jaundice, hemorrhage, or pleural effusion (n = 479). Second, fatal leptospirosis
cases were identified via the Enhanced Fatal AFI Surveillance System (EFASS) in which: a)
serum or tissue specimens collected during autopsy were tested by MAT, PCR, or immunohis-
tochemistry (IHC) [27]; and b) death certificates were reviewed for use of “leptospirosis” or
“Weil’s disease”. Third, all leptospirosis cases reported to PRDH along with a positive diagnos-
tic test result via the Notifiable Diseases Surveillance System (NDSS) were included. Last, two
commercial laboratories were queried for leptospirosis cases that tested positive by IgM dot
blot. Cases identified through more than one data source with matching names and dates of
birth were considered a single case.
Definitions
A laboratory-positive leptospirosis patient was defined as a person that had evidence of infection
with Leptospira spp. by detection of: i) antigen in a tissue specimen by IHC; ii) nucleic acid in a
serum or tissue specimen by PCR; iii)4-fold rise in MAT titer in paired serum specimens; iv)
MAT titer800 in a single serum specimen; v) anti-Leptospira IgM antibody at a private labo-
ratory; or vi) MAT titer100 but<800 in a single serum specimen. A confirmed leptospirosis
patient was defined by any of criteria i–v; a probable leptospirosis patient was defined by criteria
vi. A suspected fatal leptospirosis patient was a person who died in Puerto Rico in 2010, had the
word “leptospirosis” written on the death certificate, and had either: a) no leptospirosis diag-
nostic testing performed; or b) negative diagnostic testing performed at a commercial labora-
tory on a specimen collected within five days of illness onset.
Case-control study
Each fatal, laboratory-positive leptospirosis patient (i.e., cases) was matched by age within five
years with up to three non-fatal, hospitalized, laboratory-positive leptospirosis patients (i.e.,
controls). All available medical records–including private office, out-patient clinic, emergency
Risk Factors for Fatal Leptospirosis
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department, and inpatient hospitalizations–during the episode of illness were reviewed. Con-
trols that left the hospital against medical advice or had incomplete medical records were
replaced.
Data analysis
The frequencies of clinical, demographic and laboratory data were calculated by performing
descriptive analyses of all leptospirosis patients identified in 2010 and compared using Stu-
dent’s t-test or Chi squared test. Rates of leptospirosis by age group and municipality of resi-
dence were calculated using data from the 2010 United States Census [28]. Statistical
differences and modeling of matched case-control data were performed using exact conditional
logistic regression. Due to a limited number of matched pairs, several combinations of clinical
lab results were considered for independent predictors of fatal outcome. Normal limits of labo-
ratory values were defined by accepted standards [29].
All data analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC),
graphs were produced in SAS and Microsoft Excel (Microsoft Corp., Redmond, WA), and
maps were created using ArcView (ESRI, Redlands, CA). Specimens were not anonymized
prior to diagnostic testing to enable reporting of results to requesting physicians. Data included
in the case-control study were anonymized prior to analysis.
Results
Identification of leptospirosis patients
Among 1,133 suspected but laboratory-negative dengue cases that were selected for leptospiro-
sis diagnostic testing, 105 (9.3%) were laboratory-positive (S1 Table). Among 802 specimens
from patients tested for leptospirosis at a private laboratory, 56 (7.0%) were positive. A total of
57 non-fatal leptospirosis patients were reported via NDSS in 2010, and laboratory diagnostic
evidence was provided for 15 (26%). After consolidating individual patients identified by mul-
tiple systems, a total of 149 non-fatal, laboratory-positive leptospirosis patients were identified
in Puerto Rico in 2010 (4.0 non-fatal patients per 100,000 residents), of which 91 (61%) were
confirmed and 58 (39%) were probable leptospirosis patients. Dengue was ruled out for 134
(90%) non-fatal leptospirosis patients by rRT-PCR and/or IgM ELISA [23]; one apparent co-
infection was identified in which DENV-1 was detected by RT-PCR and anti-Leptospira spp.
IgM antibody was detected at a private laboratory.
A total of 26 fatal leptospirosis patients were identified (0.7 fatal patients per 100,000 resi-
dents), of which 21 were confirmed and five were suspected leptospirosis patients; only two
(7.7%) had been reported to PRDH. Fifteen fatal, laboratory-positive leptospirosis patients had
available kidney and liver tissue specimens, and Leptospira antigen was detected by IHC in all
15. Dengue was ruled out in 18 (86%) of the fatal, laboratory-positive leptospirosis patients and
in two (40%) of the fatal, suspected leptospirosis patients. Two patients with fatal DENV/Lep-
tospira spp. co-infection were identified [30]. Among all 26 fatal leptospirosis patients, the
most common reported causes of death included respiratory, cardiac, or renal failure, and sep-
tic shock (S2 Table).
MAT-positive specimens (n = 130) from laboratory-positive leptospirosis patients showed
strongest reactivity to serogroups including Icterohaemorrhagiae (57%), Australis (11%), Mini
(5%), Bataviae (4%), Canicola (4%), Cynopteri (2%), Pyrogenes (2%), Pomona (1%), Djasiman
(1%), and Autumnalis (1%); 12% had strongest reactivity against more than one serogroup. Of
four PCR-positive serum specimens from one fatal and three non-fatal patients, multi-locus
sequence typing [31] identified six of seven alleles suggestive of L. interrogans serovar
Risk Factors for Fatal Leptospirosis
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Icterohaemorrhagiae/Copenhageni in the specimen from the fatal patient; MLST was not suc-
cessful for the other specimens.
Demographics and epidemiology
Leptospirosis patients had illness onset in all months of the year (Fig 1). Peak incidence of iden-
tified fatal and non-fatal leptospirosis patients occurred in October, in association with the
rainy season. Most (79%) fatal and non-fatal laboratory-positive leptospirosis patients were
male. Leptospirosis patients were identified in all age groups (Fig 2). Incidence was highest in
individuals aged 40–69 years and lowest in individuals aged>80 years. Fatal patients were sig-
nificantly older than non-fatal patients (mean of 50 vs. 41 years; p = 0.02). Confirmed and
probable non-fatal leptospirosis patients were not significantly different by age (p = 0.34) or
month of illness onset (p = 0.35); however, more confirmed than probable non-fatal patients
were male (85% vs. 68%; p = 0.02). Most non-fatal (59%) and fatal (92%) leptospirosis cases
were reported to have been hospitalized. Mortality by age group was highest in those aged 60–
69 years (1.8 per 100,000 residents).
Fatal and non-fatal leptospirosis cases resided in both urban and rural municipalities across
Puerto Rico (Fig 3). In the 59 (76%) municipalities for which cases were detected, incidence
was highest in Patillas in the rainy southeast–where enhanced dengue surveillance was con-
ducted at a community health center in 2010 [23]–and in the mountainous, agricultural center
of the island. Incidence was lowest in Cabo Rojo in the arid southwest.
Risk factors for fatal outcome
A case-control study was conducted in which data from medical records were compared
between 21 laboratory-positive fatal cases and 52 age-matched, laboratory-positive, hospital-
ized but non-fatal leptospirosis controls. Cases and controls did not differ significantly by sex,
Fig 1. Date of illness onset of fatal (n = 26) and non-fatal (n = 147) leptospirosis patients identified in
Puerto Rico, 2010*. *If date of illness onset was unavailable, date of first specimen collection was used
instead. Two non-fatal patients had no available date of illness onset or date of specimen collection.
doi:10.1371/journal.pntd.0004482.g001
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occupation, or animal or environmental exposure history, nor by reported co-morbidities or
chronic medical conditions (S3 Table).
Fatal cases first sought medical care sooner after illness onset than non-fatal controls, and
more often sought care at a private or out-patient clinic (Table 1). Although controls first
sought medical care at a hospital more frequently than cases, cases were more often admitted
Fig 2. Age group of fatal (n = 26) and non-fatal (n = 146*) leptospirosis patients in Puerto Rico, 2010.
Red bars represent fatal laboratory-positive (n = 21) and suspected (n = 5) leptospirosis patients; blue bars
represent non-fatal probable (n = 58) and confirmed (n = 88) leptospirosis patients. *age was unavailable for
1 non-fatal patient.
doi:10.1371/journal.pntd.0004482.g002
Fig 3. Rate of leptospirosis patients (N = 155*) and number of fatal patients (n = 26) bymunicipality of residence, Puerto Rico, 2010.Rates were
calculated by dividing case numbers by municipality-specific populations, and grouped by quintile. *municipality of residence was unavailable for 18 non-
fatal patients
doi:10.1371/journal.pntd.0004482.g003
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or referred for admission at the first visit. Cases and controls did not differ by day post-illness
onset (DPO) of hospitalization or duration of hospital stay. Cases were more often admitted to
Table 1. Characteristics of clinical management of fatal and non-fatal leptospirosis patients, Puerto Rico, 2010.
Fatal cases Non-fatal controls
N = 21 N = 52
n (%) n (%) P-value
Medications taken before first seeking care
Acetaminophen 9 (42.9) 16 (30.8) 0.42
Antibiotic 0 (0.0) 5 (9.6) 0.33
Other* 7 (33.3) 11 (21.2) 0.38
First medical visit
DPO, median (range) 2.5 (0–10) 5 (2–14) <0.01
Facility type
Private Clinic 2 (9.5) 2 (3.9) 0.62
Out-patient clinic 8 (38.1) 2 (3.9) Reference
Hospital 11 (52.4) 47 (92.2) <0.01
Outcome
Sent home 8 (38.1) 44 (84.6) <0.01
Admitted or referred for admission 13 (61.9) 8 (15.4) Reference
Hospitalization
DPO admitted 4.5 (2–10) 6 (2–14) 0.31
Duration of hospitalization in days, median (range) 4 (1–37) 8 (0–150) 0.68
Admitted to intensive care unit 16 (76.2) 21 (40.4) 0.01
Intubated 19 (90.5) 7 (13.5) <0.01
Hemodialysis initiated 7 (33.3) 4 (7.7) 0.02
Received a blood product† 13 (61.9) 28 (53.8) 0.57
Diagnosis
“Leptospirosis” in differential at first medical visit 9 (42.9) 5 (9.6) 0.01
“Dengue” or “viral syndrome” in differential at first medical visit 15 (71.4) 31 (59.6) 0.25
“Leptospirosis” in discharge diagnosis at first medical visit 4 (19.0) 14 (26.9) 0.76
“Dengue” or “viral syndrome” in discharge diagnosis at first medical visit 7 (33.3) 26 (50.0) 0.18
“Leptospirosis” mentioned in any medical record 18 (85.7) 31 (59.6) 0.03
DPO first mentioned, median (range) 5 (2–10) 7 (2–26) 0.09
DPH first mentioned, median (range) 0.5 (0–20) 1 (0–15) 0.30
“Dengue” mentioned in any medical record 15 (71.4) 52 (100) <0.01
DPO first mentioned, median (range) 3 (1–11) 5 (2–14) 0.23
DPH first mentioned, median (range) 0 (0–4) 0 (0–2) 0.08
Medications
Penicillin-derivative antibiotic 19 (90.5) 38 (73.1) 0.62
DPO given, median (range) 4.5 (3–10) 6.0 (3–13) 0.23
DPH given, median (range) 1 (0–3) 1.0 (0–6) 0.73
Corticosteroid 9 (42.9) 33 (63.5) 0.82
DPO given, median (range) 4 (1–7) 6.0 (2–14) 0.20
DPH given, median (range) 0 (0–2) 0 (0–4) 0.58
*Other = aspirin, non-steroidal anti-inflammatory drug, statin, anti-depressant, anti-histamine, histamine H2R antagonist, nitrate, sulfonylurea
†Cases: 8 (38%) received platelets, 5 (24%) received packed red blood cells, and 4 (19%) received fresh frozen plasma; Controls: 18 (35%) received
platelets, 15 (29%) received packed red blood cells, 2 (4%) received fresh frozen plasma, and 1 (2%) received plasma.
Abbreviations: DPO = day post-illness onset; DPH = day post-illness onset of hospitalization; N = Normal
doi:10.1371/journal.pntd.0004482.t001
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the intensive care unit, intubated, and received hemodialysis (p 0.02). Blood products were
administered to more than half of cases and controls.
Cases more often had leptospirosis included in the differential diagnosis at first medical
visit (p = 0.01), whereas controls more often had “dengue” ever mentioned in any medical
record (p< 0.01). The timing with which “leptospirosis” and “dengue” were mentioned post-
illness onset and post-hospitalization did not differ between cases and controls. Antibiotics
were administered to>70% of cases and controls. Corticosteroids were administered to
roughly half of cases and controls, most frequently on the day of admission. The frequency,
clinical setting (e.g., out-patient clinic vs. hospital), and timing of administration of both anti-
biotics and corticosteroids did not significantly differ between cases and controls.
Cases presented to first medical visit with either fever or cough less often than controls
(Table 2). Similarly, cases less often developed fever throughout hospitalization. Most cases
developed jaundice, edema, leg pain, hemoptysis, and altered mental status, while fewer than
half of controls had these findings. Developing cyanosis and having a seizure were also associ-
ated with fatal outcome.
DPO of first laboratory values did not differ significantly between cases and controls. As
compared to controls, at first medical visit cases had significantly elevated white blood cell
(WBC) count, proportion of neutrophils, BUN, creatinine, and total bilirubin, and decreased
bicarbonate and albumin (Fig 4, S4 Table). For cases, these values were also more frequently
outside of normal ranges. Throughout the clinical course, cases had significantly elevated WBC
count, proportion of neutrophils, BUN, and creatinine, and decreased hematocrit, bicarbonate,
albumin, prothrombin time (PT), and partial thromboplastin time (PTT).
Multivariable model of early indicators of fatal outcome
Because fever and cough were the only early clinical signs and symptoms that were associated
with fatal outcome and may be spurious findings (see Discussion), only laboratory values were
included as parameters in the model. BUN and PTT were removed from the model due to
higher specificity of creatinine for kidney injury as opposed to dehydration and infrequency of
the test being requested at initial patient presentation, respectively. Clinical laboratory values
significantly associated with fatal outcome at first presentation as compared to controls
included: decreased serum bicarbonate with elevated serum creatinine, elevated WBC count, or
decreased platelet count; and elevated WBC count with elevated serum creatinine (Table 3).
Discussion
Enhanced surveillance demonstrated a high rate of morbidity and mortality due to leptospiro-
sis in Puerto Rico in 2010 (4.7 and 0.7 cases per 100,000 residents, respectively). Comparable
incidences have been observed in other regions of the Caribbean that have conducted enhanced
surveillance [32–36], which also demonstrated highest burden in older male agricultural work-
ers and the unemployed [2, 36]. Although the patients identified in Puerto Rico reflected the
expected clinical characteristics of severe leptospirosis (i.e., pulmonary hemorrhage, acute kid-
ney injury, and/or septic shock with multi-organ failure), under recognition and underreport-
ing of leptospirosis cases was prominent, as one-third of patients were never diagnosed with
leptospirosis and two-thirds were not reported to public health authorities. These findings
together demonstrate that leptospirosis remains a neglected tropical disease in Puerto Rico.
Several missed opportunities for early clinical intervention were identified in this study.
First, although fatal cases sought care earlier and were more often diagnosed with leptospirosis
at first medical visit; however, fatal patients less often first sought care at a hospital, and were
not admitted to the hospital any sooner than non-fatal patients. Thus, delayed hospital
Risk Factors for Fatal Leptospirosis
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admission may have contributed to fatal outcome, as has been previously reported [12, 13].
However, we saw no evidence that this delay was associated with the timing of initiation of
antibiotic therapy, which did not differ between cases and controls. Although prospective
Table 2. Signs and symptoms of fatal (n = 21) and non-fatal (n = 52) leptospirosis patients at first presentation and during hospitalization, Puerto
Rico, 2010.
Signs or symptom At first presentation During hospitalization
Fatal Non-fatal P-value Fatal Non-fatal P-value
(N = 21) (N = 52) (N = 21) (N = 52)
n (%) n (%) n (%) n (%)
Fever* 10 (47.6) 31 (59.6) 0.01 15 (71.4) 49 (94.2) 0.03
Weakness/lethargy 9 (42.9) 27 (51.9) 0.58 19 (90.5) 46 (88.5) 0.29
Headache 9 (42.9) 26 (50.0) 0.13 14 (66.7) 41 (78.8) 1.00
Eye pain 2 (9.5) 4 (7.7) 0.58 5 (23.8) 9 (17.3) 0.34
Conjunctival suffusion 0 (0.0) 8 (15.4) 0.07 3 (14.3) 12 (23.1) 0.67
Conjunctival hemorrhage 0 (0.0) 2 (3.8) 1.00 2 (9.5) 4 (9.6) 0.58
Icteric sclera 6 (28.6) 10 (19.2) 1.00 14 (66.7) 21 (40.4) 0.37
Jaundice 6 (28.6) 11 (21.2) 0.65 17 (81.0) 22 (42.3) 0.02
Cyanosis 2 (9.5) 0 (0.0) 0.08 6 (28.6) 1 (1.9) <0.01
Petechia 1 (4.8) 9 (17.3) 0.65 6 (28.6) 15 (28.8) 0.76
Purpura 3 (14.3) 3 (5.8) 0.17 5 (23.8) 8 (15.4) 1.00
Rash 1 (4.8) 9 (17.3) 1.00 3 (14.3) 16 (30.8) 0.14
Dehydration 8 (38.1) 22 (42.3) 0.06 16 (76.2) 41 (78.8) 1.00
Edema 5 (23.8) 10 (19.2) 0.70 16 (76.2) 16 (30.8) <0.01
Effusion 3 (14.3) 10 (19.2) 0.61 7 (33.3) 18 (34.6) 1.00
Ascites 2 (9.5) 4 (7.7) 1.00 4 (19.0) 5 (9.6) 0.31
Cardiac effusion 1 (4.8) 1 (1.9) 0.33 1 (4.8) 1 (1.9) 0.33
Anorexia 6 (28.6) 19 (36.5) 0.58 13 (61.9) 32 (61.5) 0.48
Vomiting 10 (47.6) 18 (34.6) 1.00 16 (76.2) 30 (57.7) 0.14
Diarrhea 10 (47.6) 14 (26.9) 0.53 15 (71.4) 29 (55.8) 0.13
Hepatomegaly 2 (9.5) 6 (11.5) 1.00 4 (19.0) 10 (19.2) 1.00
Splenomegaly 1 (4.8) 5 (9.6) 1.00 1 (4.8) 8 (15.4) 0.66
Muscle pain 15 (71.4) 32 (61.5) 1.00 19 (90.5) 49 (94.2) 1.00
Leg pain 7 (33.3) 11 (21.2) 0.25 15 (71.4) 20 (38.5) 0.01
Dyspnea 6 (28.6) 14 (26.9) 0.66 18 (85.7) 27 (51.9) 0.07
Cough 2 (9.5) 15 (28.8) 0.01 8 (38.1) 30 (57.7) 0.17
Altered mental status 6 (28.6) 7 (13.5) 0.45 18 (85.7) 12 (23.1) <0.01
Meningitis 0 (0.0) 0 (0.0) —† 0 (0.0) 1 (1.9) —†
Encephalitis 2 (9.5) 0 (0.0) 0.50 2 (9.5) 1 (1.9) 0.17
Seizure 2 (9.5) 1 (1.9) 1.00 5 (23.8) 1 (1.9) 0.03
Epistaxis 1 (4.8) 1 (1.9) 1.00 5 (23.8) 3 (5.8) 0.10
Hematemesis 1 (4.8) 2 (3.8) 1.00 5 (23.8) 7 (13.5) 0.67
Hemoptysis 2 (9.5) 4 (7.7) 0.50 11 (52.4) 8 (15.4) 0.03
Hematuria 6 (28.6) 21 (40.4) 0.27 14 (66.7) 36 (69.2) 0.77
Melena 2 (9.5) 4 (7.7) 1.00 6 (28.6) 10 (19.2) 0.67
Cerebral bleed 0 (0.0) 0 (0.0) —† 0 (0.0) 1 (1.9) —†
*Subjective or objective
†Cannot be calculated due to missing information.
doi:10.1371/journal.pntd.0004482.t002
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clinical trials of antibiotics have not demonstrated a clear benefit to leptospirosis patient out-
come [37], this should not preclude administration of antibiotics to patients with suspected
Fig 4. Box plots of selected laboratory values of fatal (n = 21) and non-fatal (n = 52) leptospirosis patients included in a case-control study, Puerto
Rico, 2010.Medical records from all health care visits were abstracted, and first and worst laboratory values (S4 Table) were compared. The median value is
indicated by the horizontal line within each box; mean value is indicated by the diamond; 25th and 75th interquartile range (IQR) are indicated by the bottom
and top edges of the box, respectively; whiskers indicate the range of values within 1.5 times the value of the IQR. P values indicate statistical significant
differences between fatal and non-fatal patients. Shaded horizontal lines indicate normal reference laboratory values.
doi:10.1371/journal.pntd.0004482.g004
Table 3. Multivariate analysis for laboratory values associated with fatal leptospirosis patients, Puerto Rico, 2010.
Model Clinical test 1 OR (95% CI) P-value Clinical test 2 OR (95% CI) P-value Model P-value
1 Decreased serum bicarbonate 0.51 (0.12–0.91) 0.006 Elevated serum creatinine 2.93 (1.03–11.72) 0.042 <0.001
2 Decreased serum bicarbonate 0.50 (0.21–0.81) <0.001 Decreased platelet count 1.02 (1.00–1.05) 0.015 <0.001
3 Decreased serum bicarbonate 0.19 (<0.01–0.78) <0.001 Elevated WBC count 1.25 (1.03–1.75) 0.025 <0.001
4 Elevated WBC count 1.17 (1.03–1.38) 0.014 Elevated serum creatinine 2.09 (1.14–4.71) 0.010 0.001
Abbreviations: OR = odds ratio; CI = confidence interval; WBC = white blood cell
doi:10.1371/journal.pntd.0004482.t003
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leptospirosis [10]. Last, roughly half of all leptospirosis patients were given corticosteroids,
which may result in increased risk of hemorrhage and immunosuppression. A recent system-
atic review demonstrated no clear benefit to leptospirosis patient outcome by administering
corticosteroids [38]; however, prospective clinical trials have yet to be conducted.
To improve recognition of leptospirosis and thereby mediate earlier admission for care, cli-
nicians should be aware of patient characteristics and clinical indicators associated with severe
leptospirosis. Most previous studies that identified risk factors associated with death due to lep-
tospirosis relied on data collected during the final medical visit, which may be suboptimal for
identification of early indicators of fatal outcome. After matching for age and status of hospital-
ization, no patient characteristics, including gender and history of smoking [15, 39], were sig-
nificantly associated with fatal outcome in this study. Similar to previously studies [5, 8, 12,
16–18], we observed that jaundice, hemoptysis, acute kidney injury, and dyspnea or respiratory
insufficiency were significantly associated with fatal outcome in this study, though not at initial
medical visit. Therefore, the utility of these signs and symptoms may be limited in early identi-
fication of leptospirosis patients at risk for fatal outcome. Unexpected risk factors associated
with fatal leptospirosis in this study were absence of cough and fever at first health care visit
and lack of development of fever throughout hospitalization. Cough at initial presentation has
been previously associated with protection from fatal outcome [12], though for unclear rea-
sons. Potential explanations for lack of fever being associated with fatal outcome include
incomplete capture of fever history, self-administration of antipyretics, or earlier entry into
decompensated shock. Further studies should address the association of these signs and symp-
toms with fatal leptospirosis.
A prominent utility of this study was the association of common clinical laboratory values
with fatal leptospirosis, specifically decreased bicarbonate with decreased platelet count and
increased WBC count with elevated creatinine, all of which have been previously associated
with severe leptospirosis [5, 8, 16–18, 40]. However, we did not observe that elevated serum
potassium either at first presentation or at any point during hospitalization was associated with
fatal outcome, as has previously been reported [40–43]. Nonetheless, the values of the labora-
tory markers of fatal outcome identified in this study tended to be farther outside of normal
ranges at first presentation in fatal as compared to non-fatal patients, suggesting that patients
with fatal leptospirosis may have progressed to severe disease more rapidly. In line with this,
fatal patients were more likely to be diagnosed with leptospirosis earlier than were non-fatal
patients, who were more likely to ever be diagnosed with dengue. Because previous studies
associated elevated WBC count and elevated serum creatinine with leptospirosis as compared
to dengue [20, 44–46], these clinical laboratory values may have utility in not only differentiat-
ing leptospirosis patients from dengue patients, but also in identifying leptospirosis patients at
risk for poor outcome. Future studies should evaluate the prospective benefit of using such
combinations of laboratory values to improve patient outcome through early identification and
admission.
Compared to previous studies that have identified risk factors associated with severe or fatal
outcome in leptospirosis patients, a major strength of this study was the design of the case-con-
trol study. By reviewing medical records from each health care visits made by patients included
in the case-control study, and not solely those from the patients’ hospitalization, we avoided
biasing results towards points in patients’ illness in which they were likely to be more clinically
severe (i.e., at point of hospitalization). This also enabled identification of clinical indicators
that would be of clinical utility before patients were hospitalized, which could thereby mediate
more rapid diagnosis and/or hospitalization of patients at-risk for fatal outcome. Moreover, by
closely matching patients by age we avoided identification of risk factors that may be associated
with older populations. These aspects of study design together may account for some
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differences in factors associated with fatal outcome identified by this study as compared to pre-
vious studies that did not control for age [3, 8, 12, 16, 17, 47]. Additional strengths of this study
include: conducting surveillance for fatal leptospirosis cases by testing specimens collected dur-
ing autopsy of patients that died following an AFI, without which many fatal cases would not
have been diagnosed; and utilizing multiple surveillance systems to identify fatal and non-fatal
leptospirosis patients and subsequently comparing them using a standardized instrument for
chart abstraction.
Conversely, one limitation of this study is potential misclassification of some probable lep-
tospirosis patients due to the presence of pre-existing neutralizing antibody. However, because
several thousand suspected but dengue-negative cases reported to PRDH in 2010 were not
tested for evidence of leptospirosis, the incidence of leptospirosis identified herein is likely an
underestimate. Also, although previous studies have demonstrated that predictors of fatal lep-
tospirosis include oliguria [8, 17, 18, 41, 48, 49] and anuria [12], we were unable to explore
these factors due to the unavailability of routine clinical data on urine output. Moreover, due to
limited sample size, we were also unable to identify specific cut-offs of clinical laboratory values
associated with fatal outcome. Last, we were unable to evaluate DENV/Leptospira spp. co-infec-
tion as a risk factor for death since most leptospirosis cases were identified by screening sus-
pected dengue cases that tested laboratory-negative for dengue.
Clinical trainings to improve early recognition of leptospirosis patients, interpretation of
diagnostic test results, need for case reporting, and clinical management should be conducted
among clinicians working in both out-patient and in-patient settings in Puerto Rico. Since
improvements in case surveillance and clinical awareness have been associated with decreases
in patient mortality due to leptospirosis [6], such trainings may also be needed in other areas of
the tropics where clinical under recognition of leptospirosis may be high [2]. Population-based
serosurveys should be conducted to accurately quantitate the burden of leptospirosis and iden-
tify modifiable risk factors associated with infection, including identification of the animal res-
ervoirs that transmit Leptospira spp. to humans. Such findings can be used to develop
educational campaigns to inform the public of population-specific strategies that can be
employed to reduce their risk of leptospirosis.
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